Loading
Three trials with three different antibodies agree: adding immunotherapy to first chemotherapy for advanced endometrial cancer roughly triples progression-free time in dMMR tumours and helps the rest modestly.
Adding a PD-1 or PD-L1 antibody to first-line carboplatin-based chemotherapy for advanced or recurrent endometrial cancer is a combination pairing supported by three positive phase 3 trials with three different antibodies: RUBY with dostarlimab, NRG-GY018 / KEYNOTE-868 with pembrolizumab, and DUO-E with durvalumab with or without olaparib. Tumours with mismatch repair deficiency carry thousands of neoantigens and gain the most, while chemotherapy provides antigen release and lymphodepletion that appear to extend a more modest benefit into mismatch repair-proficient disease. RUBY also demonstrated an overall survival benefit. The consistency across these trials makes it the most reliably replicated regimen in gynaecological oncology.
Shares Mismatch-repair-deficient endometrial cancer, Advanced or recurrent endometrial cancer, Dostarlimab, Endometrial cancer.
Shares Mismatch-repair-deficient endometrial cancer, Advanced or recurrent endometrial cancer, Endometrial cancer, Carboplatin.
Shares Mismatch-repair-deficient endometrial cancer, Endometrial cancer, Carboplatin, Pembrolizumab.
Shares Mismatch-repair-deficient endometrial cancer, Advanced or recurrent endometrial cancer, Dostarlimab, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR).
Shares Advanced or recurrent endometrial cancer, Durvalumab, Endometrial cancer, Immune checkpoint inhibitors.
Shares DUO-E / GOG-3041 / ENGOT-EN10, Advanced or recurrent endometrial cancer, Durvalumab, Carboplatin.
Shares NRG-GY018 / KEYNOTE-868, Endometrial cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Carboplatin, Pembrolizumab.